ATE350044T1 - Thrombopoietinmimetika - Google Patents

Thrombopoietinmimetika

Info

Publication number
ATE350044T1
ATE350044T1 AT00965329T AT00965329T ATE350044T1 AT E350044 T1 ATE350044 T1 AT E350044T1 AT 00965329 T AT00965329 T AT 00965329T AT 00965329 T AT00965329 T AT 00965329T AT E350044 T1 ATE350044 T1 AT E350044T1
Authority
AT
Austria
Prior art keywords
mammal
invented
thrombopoietin mimetics
mimetics
thrombopoietin
Prior art date
Application number
AT00965329T
Other languages
English (en)
Inventor
Kevin J Duffy
Juan I Luengo
Nannan Liu
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of ATE350044T1 publication Critical patent/ATE350044T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
    • C07D231/48—Oxygen atom in position 3 or 5 and nitrogen atom in position 4 with hydrocarbon radicals attached to said nitrogen atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Television Systems (AREA)
  • Vehicle Body Suspensions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00965329T 1999-09-24 2000-09-22 Thrombopoietinmimetika ATE350044T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15595899P 1999-09-24 1999-09-24

Publications (1)

Publication Number Publication Date
ATE350044T1 true ATE350044T1 (de) 2007-01-15

Family

ID=22557467

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00965329T ATE350044T1 (de) 1999-09-24 2000-09-22 Thrombopoietinmimetika

Country Status (8)

Country Link
US (1) US6552008B1 (de)
EP (1) EP1223944B1 (de)
JP (1) JP2003509462A (de)
AT (1) ATE350044T1 (de)
AU (1) AU771460B2 (de)
DE (1) DE60032783T2 (de)
ES (1) ES2279769T3 (de)
WO (1) WO2001021180A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
US6887890B2 (en) 2000-05-30 2005-05-03 Chugai Seiyaku Kabushiki Kaisha Compounds exhibiting thrombopoietin-like activities
JP2004520302A (ja) * 2000-12-19 2004-07-08 スミスクライン・ビーチャム・コーポレイション トロンボポエチン模倣物
MY142390A (en) 2002-05-22 2010-11-30 Glaxosmithkline Llc 3' - [(2z)-[1-(3,4-dimethylphenyl)-1,5- dihydro-3- methyl-5-0xo-4h-pyrazol-4- ylidene]hydrazino]-2' -hydroxy -[1,1' -biphenyl]-3-carboxylic acid bis-(monoethanolamine)
EP1552828A4 (de) 2002-08-14 2007-01-24 Nissan Chemical Ind Ltd Thrombopoetin-rezeptor-aktivator und verfahren zu seiner herstellung
ES2781475T3 (es) * 2002-09-18 2020-09-02 Janssen Pharmaceuticals Inc Métodos para aumentar la producción de células madre hematopoyéticas y plaquetas
TWI324593B (en) 2002-10-09 2010-05-11 Nissan Chemical Ind Ltd Pyrazolone compounds and thrombopoietin receptor activator
US20090298179A1 (en) * 2003-04-29 2009-12-03 Connie Erickson-Miller Methods For Treating Degenerative Diseases/Injuries
EP1622609A4 (de) * 2003-04-29 2008-09-03 Smithkline Beecham Corp Verfahren zur behandlung von degenerativen erkrankungen/verletzungen
US20090143453A1 (en) * 2003-04-29 2009-06-04 Connie Erickson-Miller Methods for treating degenerative diseases/injuries
US20100004302A1 (en) * 2003-04-29 2010-01-07 Connie Erickson-Miller Methods for Treating Degenerative Diseases/Injuries
US20090048318A1 (en) * 2003-04-29 2009-02-19 Connie Erickson-Miller Methods for treating degenerative diseases/injuries
AU2004238868B2 (en) * 2003-05-12 2010-01-21 Affymax, Inc. Peptides that bind to the erythropoietin receptor
CN1820024B (zh) 2003-05-12 2011-06-22 阿费麦克斯公司 新的聚(乙二醇)修饰的化合物及其用途
ATE428727T1 (de) 2003-05-12 2009-05-15 Affymax Inc Neue, an den erythropoietinrezeptor bindende peptide
US7919118B2 (en) 2003-05-12 2011-04-05 Affymax, Inc. Spacer moiety for poly (ethylene glycol) modified peptide based compounds
SG131110A1 (en) 2003-08-28 2007-04-26 Ortho Mcneil Pharm Inc Peptides and compounds that bind to thrombopoietin receptors
US7723295B2 (en) 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
TW200526638A (en) 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
WO2005118551A2 (en) * 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
CA2583764C (en) 2004-10-25 2009-06-09 Ligand Pharmaceuticals, Inc. Thrombopoietin activity modulating compounds and methods
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
JP2008519858A (ja) * 2004-11-11 2008-06-12 アフィーマックス・インコーポレイテッド エリスロポエチンレセプターに結合する新規ペプチド
US7125446B2 (en) * 2004-11-19 2006-10-24 Eastman Kodak Company Yellow dyes for ink jet inks
CA2588979C (en) 2004-12-08 2013-01-22 Nissan Chemical Industries, Ltd. 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators
US8134013B2 (en) 2004-12-14 2012-03-13 Nissan Chemical Industries, Ltd. Amide compound and thrombopoietin receptor activator
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
WO2007010954A1 (en) 2005-07-15 2007-01-25 Nissan Chemical Industries, Ltd. Thiophene compounds and thrombopoietin receptor activators
KR101290484B1 (ko) 2005-07-20 2013-07-26 닛산 가가쿠 고교 가부시키 가이샤 피라졸 화합물 및 트롬보포이에틴 수용체 활성화제
JP5205967B2 (ja) 2005-11-07 2013-06-05 日産化学工業株式会社 ヒドラジド化合物及びトロンボポエチンレセプター活性化剤
CA2630234A1 (en) * 2005-11-23 2007-05-31 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
JP5157900B2 (ja) 2006-06-07 2013-03-06 日産化学工業株式会社 含窒素ヘテロ環化合物及びトロンボポエチンレセプター活性化剤
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
EP2118127A4 (de) * 2007-01-31 2010-12-01 Affymax Inc Linker auf stickstoffbasis zur bindung modifizierender gruppen an polypeptide und andere makromoleküle
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
CA2728063A1 (en) * 2008-06-19 2009-12-23 Astrazeneca Ab Pyrazole compounds 436
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
US8680150B2 (en) * 2009-05-28 2014-03-25 Ligand Pharmaceuticals, Inc. Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors
SG176088A1 (en) 2009-05-29 2011-12-29 Glaxosmithkline Llc Methods of administration of thrombopoietin agonist compounds
WO2011098095A1 (en) 2010-02-09 2011-08-18 Aplagen Gmbh Peptides binding the tpo receptor
WO2012102937A2 (en) 2011-01-25 2012-08-02 Irm Llc Compounds that expand hematopoietic stem cells
EP2788476B1 (de) 2011-12-08 2019-05-22 Fred Hutchinson Cancer Research Center Zusammensetzungen und verfahren zur erhöhten erzeugung von hämatopoietischen stamm-/vorläuferzellen
EP2807165B1 (de) 2012-01-27 2019-05-15 Université de Montréal Pyrimido-[4,5-b-]indolderivate und verwendung davon in der expansion von hämatopoetischen stammzellen
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
JP6762233B2 (ja) 2014-04-22 2020-09-30 ウニヴェルシテ ド モントリオールＵｎｉｖｅｒｓｉｔｅ Ｄｅ Ｍｏｎｔｒｅａｌ 化合物および造血幹細胞および／または造血前駆細胞の増大におけるその使用
JP6658535B2 (ja) 2014-10-31 2020-03-04 日産化学株式会社 リガンド結合繊維及び当該繊維を用いた細胞培養基材

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2950273A (en) * 1956-11-20 1960-08-23 Agfa Ag Process for the production of symmetrical and unsymmetrical azo compounds
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives

Also Published As

Publication number Publication date
EP1223944A4 (de) 2002-10-30
EP1223944A1 (de) 2002-07-24
WO2001021180A1 (en) 2001-03-29
EP1223944B1 (de) 2007-01-03
JP2003509462A (ja) 2003-03-11
US6552008B1 (en) 2003-04-22
AU771460B2 (en) 2004-03-25
ES2279769T3 (es) 2007-09-01
DE60032783T2 (de) 2007-12-06
DE60032783D1 (en) 2007-02-15
AU7606400A (en) 2001-04-24

Similar Documents

Publication Publication Date Title
ATE350044T1 (de) Thrombopoietinmimetika
DE60025632D1 (de) Thrombopoietin-mimetika
DE60031714D1 (de) Thrombopoietin-mimetika
MY136707A (en) Thrombopoietin mimetics
WO2002049413A3 (en) Thrombopoietin mimetics
HK1043472A1 (zh) 血小板减少症拟态
WO2004054515A3 (en) Thrombopoietin mimetics
EP1133291A4 (de) Verfahren zur behandlung der thrombozytopenie
CY1108221T1 (el) Μεθοδος για την αναπαραγωγη πλευρομουτιλινων
DE60124684D1 (de) Sulfonamido-substituierte verbrückte bicycloalkylderivative
DE60001421D1 (de) Behandlung von abgas
DE60101265D1 (de) Behandlung von augenschmerzen
EP1610778A4 (de) Behandlung von benigner prostatahyperplasie
ATE203519T1 (de) Chinolinderivate als antimalariamittel
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
EP1117431A4 (de) Behandlung von acidose
EP1441761A4 (de) Verfahren zur prävention und behandlung von infektionen mit dem flavivirus bei tieren
DE60103685D1 (de) Behandlung von Poriomania
CY1106363T1 (el) Χρηση του ενepγοποιημενου παραγοντα πηξης vii για την αγωγη των επαγομενων απο θρομβολυτικη θepαπεια μειζονων αιμορραγιων
ATE302008T1 (de) Behandlung von entzündlichen erkrankungen
EA200100785A1 (ru) Шипучие слабительные средства
DE60125035D1 (de) Behandlung von plasmid-haltigen lösungen
LU91009B1 (de) Behandlung von Verbrennungen
ATE294590T1 (de) Verwendung von interleukin-11 zur behandlung von hämoragischem schock
EP1221951A4 (de) Behandlung von pankreas-erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties